The effects of pregnancy on the pharmacokinetics of infliximab and adalimumab in inflammatory bowel disease.

Cynthia H-T SeowY LeungN Vande CasteeleE Ehteshami AfsharD TanyingohG BindraM J StewartP L BeckGilaad G KaplanS GhoshR Panaccione

Published in: Alimentary pharmacology & therapeutics (2017)

Infliximab levels rise during pregnancy, whereas adalimumab levels remain stable after accounting for changes in albumin, BMI and CRP. Therapeutic drug monitoring in the second trimester may be useful in guiding dosing in the third trimester.

Keyphrases

ulcerative colitis
preterm birth
pregnancy outcomes
rheumatoid arthritis
juvenile idiopathic arthritis
gestational age
body mass index
pregnant women
hidradenitis suppurativa
physical activity
systemic lupus erythematosus